Immune Netw.  2007 Sep;7(3):109-116. 10.4110/in.2007.7.3.109.

B Cells Transduced with HPV16 E6/E7-expressing Adenoviral Vector Can Efficiently Induce CTL-dependent Anti-Tumor Immunity

• Kim YS
• Ko HJ
• Kim YJ
• Han SH
• Lee JM
• Chang WS
• Jin HT
• Sung YC
• Kang CY

• KMID: 1513196
• DOI: http://doi.org/10.4110/in.2007.7.3.109

Abstract

BACKGROUND: Human papillomavirus (HPV) infection is responsible for cervical cancer, a common cancer in women. Since HPV infection and cancer development are controlled by the host immune system, immunotherapy against HPV can be helpful in preventing or treating HPV-associated cervical cancer. Two oncoproteins of HPV16, E6 and E7, are promising targets for immunotherapy against cervical cancer, because they are constitutively expressed in cervical cancer.
METHODS
Since cellular vaccines using B cells as well as dendritic cells offer an efficient approach to cancer immunotherapy, we opted to use B cells. We evaluated the immunogenicity and anti-tumor effects of a B cell vaccine transduced with HPV16 E6/E7-expressing adenovirus.
RESULTS
Vaccination with HPV16 E6/E7-transduced B cells induced E6/E7-specific CD8+ T cell-dependent immune responses and generated anti-tumor effects against E6/E7-expressing TC-1 tumor. The anti-tumor effect induced by this B cell vaccine was similar to that elicited by DC vaccine, showing that B cells can be used as an alternative to dendritic cells for cellular vaccines.
CONCLUSION
Thisstudy has shown the feasibility of using B cells as immunogenic APCs and the potential for developing prophylactic and therapeutic vaccines against HPV-associated cervical cancer using a B cell vaccine transduced with adenovirus expressing HPV16 E6/E7.

Keyword

HPV16 E6/E7; adenoviral vector; B cells; anti-tumor immunity

MeSH Terms

Adenoviridae
B-Lymphocytes*
Dendritic Cells
Female
Humans
Immune System
Immunotherapy
Oncogene Proteins
Uterine Cervical Neoplasms
Vaccination
Vaccines
Oncogene Proteins
Vaccines